Clearside to showcase Suprachoroidal Platform progress across three phase 3 programs at CTS 2025
Clearside Biomedical, Inc, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that the use of its SCS delivery platform will be featured in multiple presentations at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025 in Las Vegas, Nevada.
Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development, commented, “Our proprietary SCS Microinjector® platform is an established, in-office solution for delivering vision-preserving therapies to the back of the eye. The pipeline of promising clinical programs using our platform underscores its versatility across multiple treatment modalities. We remain committed to redefining care with therapies that offer both extended durability and flexible dosing to address serious retinal diseases.”
Presentations Related to Clearside and its Development Partners
Title: Suprachoroidal CLS-AX for nAMD: Phase 3 Program Update
Presented by: Sobha Sivaprasad, MD, Professor of Retinal Clinical Research, Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK
Partner: REGENXBIO
Title: Update on One-Time Suprachoroidal ABBV-RGX-314 for the Treatment of DR
Presented by: Anna Abolian, OD, Senior Medical Director, Clinical Development Lead, REGENXBIO Inc.
Partner: Aura Biosciences
Title: Bel-sar – a New Treatment Paradigm in Choroidal Melanoma: Update on the Global Phase 3 CoMpass Trial
Presented by: Jennifer Lim, MD, Professor of Ophthalmology, Director, Retina Service,
Department of Ophthalmology and Visual Sciences, University of Illinois School of Medicine
About CLS-AX (axitinib injectable suspension)
Clearside is developing CLS-AX as a longer-acting therapy for the treatment of retinal diseases. CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma, that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in Phase 1/2a and Phase 2b wet AMD clinical trials in which CLS-AX was well tolerated and demonstrated a positive safety profile. With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers by compartmentalizing axitinib behind the retina, thereby limiting drug exposure to the front of the eye.
